title: Effect of arsenic trioxide on rat hepatocellular carcinoma and its renal cytotoxity.
abstract: OBJECTIVE
  To study the effect of arsenic trioxide (As(2)O(3)) on rat experimental hepatocellular carcinoma and its renal cytotoxicity.
  
  
  METHODS
  The hepatocellular carcinoma model was established by diethaylnitrosamine perfusion in stomach of 120 Wistar rats, and the treatment began at the end of 20 weeks. Before the treatment, the rat models were randomly divided into 5 groups. In the treatment groups, three doses of As(2)O(3) were injected into rat abdominal cavity; the total time of drug administration was 4 weeks. Cisplatin control or the blank group was injected into abdominal cavity with equal amount of cisplatin or saline at the same time, respectively. On the 7th, 14th and 28th day after the treatment, the hepatocellular carcinoma nodules were obtained and the morphologic changes of hepatocellular carcinoma cells were observed under light and electron microscopes; Immunohistochemistry (S-P methods) was employed to detect the expression of bcl-2, bax and PCNA in hepatocellular carcinoma tissues; flow cytometry (TUNEL assay) was used to detect the apoptosis of liver cancer cells and the change of cytokinetics. On the 28th day, the renal was obtained and its histologic change was observed under light microscope, and immunohistochemistry (SP stain) was also employed to detect the expression of bcl-2 and PCNA. Cisplatin and saline solution were used as the control.
  
  
  RESULTS
  As(2)O(3) could induce the apoptosis of rat liver cancer cells and exhibited typical morphologic changes. The incidence of apoptosis of hapatocellular carcinoma cells was elevated (P=0.001). The elevation was higher in the group of middle-dose of As(2)O(3) (1 mg/kg(-1)) significantly than the other arsenic groups and the controls (P=0.001). Large dose of As(2)O(3) (5 mg/kg(-1)) was able to arise the incidence of apoptosis, but also produced a large amount of necrosis and inflammatory reaction. Middle dose of As(2)O(3) dramatically increased the cell number in G2/M phase (P=0.0001), and apoptosis happened apparently. The expression of bcl-2 and bax was related to the dose of As(2)O(3). With the up-regulation of apoptotic incidence, the ratio of bcl-2/bak decreased. But the incidence of apoptosis was not the highest status and the ratio of bcl-2/bax was at the lowest when the highest-dose of As(2)O(3) was used. There was significant difference among the PCNA indexes (PCNA LI) of the five groups. Of them, three arsenic groups all showed decrease of different degrees, and this down-regulation was most obvious in group A. There was significant difference among the three groups (P=0.016). Under the light microscope, the rat kidney in the cisplatin group exhibited tubular epithelium swelling and degeneration, protein casts in collecting tubules; While all arsenic groups didn't show the significant changes (P=0.013). In the arsenic groups, the expression of bcl-2 in the renal tubular epithelium was increased (P=0.005), no obvious changes happened to PCNA LI. But in the group of cisplatin, the PCNA LI increased significantly (P=0.001).
  
  
  CONCLUSIONS
  As(2)O(3) can induce apoptosis of rat hepatocellular carcinoma cells. And there is optimum dose; too high dose will induce the cytotoxic effect, while certain dose of As(2)O(3) is able to block the cell cycle at G2/M phase. As(2)O(3) had the most remarkable influence on G2/M cells, and it can also induce apoptosis to cells at other phases. As(2)O(3) can restrain the proliferation of rat hepatocellular carcinoma cells, in a dose-time dependent manner; Compared with cisplatin, As(2)O(3) didn't show obvious renal toxicity, which was related to the increasing expression of bcl-2 in renal tubular epithelium, the inhibition of apoptosis and the anti-oxidation effects.
authors.affiliation: Department of Surgery of Dagang Hospital 300270, Tianjin, China. wsss@public.tpt.tj.cn
authors.forename: Shao-Shan
authors.initials: SS
authors.lastname: Wang
authors.forename: Ti
authors.initials: T
authors.lastname: Zhang
authors.forename: Xi-Lu
authors.initials: XL
authors.lastname: Wang
authors.forename: Li
authors.initials: L
authors.lastname: Hong
authors.forename: Qing-Hui
authors.initials: QH
authors.lastname: Qi
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity; D017209:Apoptosis / Q000187:drug effects; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D002945:Cisplatin / Q000627:therapeutic use / Q000633:toxicity; D005260:Female; D007150:Immunohistochemistry; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D010087:Oxides / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity*; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D018809:Proliferating Cell Nuclear Antigen; D019253:Proto-Oncogene Proteins c-bcl-2; D002945:Cisplatin; D000077237:Arsenic Trioxide